Down 32% in 3 months while the S&P 500 was flat.
−1Long-term trend
AXSM's Quality Score fell 1 point on Mon, Nov 2, to 3.
Follow AXSM's trial news. Pro members can get an alert when Axsome Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Free cash flow -$72M on $777M of sales |
| Latest filing | 8-K, Nov 2 |
ReportThis morning: sales of $259.7M; a loss of $0.25 a share. Past reports ›
In the newsAxsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Expected to report Mon Feb 22, before the open
$320M in cash
Chief Operating Officer Mark L. Jacobson sold 10,000 shares on Sep 3, under a planned sale. 16 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
AXSM is #81 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 81 |
Sales over four quarters against a year before: AXSM +57%, TNGX +121%, TVTX +77%.
Expected to report Mon Feb 22, before the open (in 112 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $259.7M, 52% more than a year ago; a loss of $0.25 a share, from $0.94.
“The increase primarily reflects commercialization activities for AUVELITY and SYMBRAVO.”
AXSM's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation”
From its results filing (SEC filing · Nov 2)
Sales grew 134% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 7% a year over 3 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Nov 2, 2026 | -5.0% | -5.8% | open |
| Aug 10, 2026 | +1.5% | +3.8% | +0.4% |
| May 4, 2026 | +2.6% | +8.3% | +5.3% |
Sales grew every year from 2022 to 2025, to $638M. It lost money in each of the four years.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: AXSM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
“Our industry is highly competitive and subject to rapid and significant technological change.”
AXSM scores 3 today, which Breakaway calls Below Average. It is #81 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 32% in 3 months while the S&P 500 was flat. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AXSM scores 3 today, which Breakaway calls Below Average (0 to 5). That is #81 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AXSM's 3.
Expected to report Mon Feb 22, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. AXSM closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.